PDSB — PDS Biotechnology Share News
0.000.00%
Last trade - 00:00Brief: PDS Biotech Plans To Initiate Phase 3 Study Evaluating PDS0101 With KEYTRUDA
Brief: PDS Biotech Reports 2022 Financial Results
PDS Biotechnology Corp reports results for the quarter ended in December - Earnings Summary
PDS Biotechnology Corp expected to post a loss of 29 cents a share - Earnings Preview
Brief: PDS Biotechnology Corp Says Does Not Hold Any Cash Or Securities At SVB
Brief: PDS Biotech Publishes Study Linking Induced Changes In Immune Responses With Clinical Outcomes In International Immunopharmacology Journal
U.S. STOCKS ON THE MOVE-AES, Opera, Lucira Health
PDS Biotech rises after positive FDA meeting for cancer therapy
Brief: PDS Biotech Completes Successful Meeting With FDA For Triple Combination Of Pds0101, Pds0301 And A Commercial Immune Checkpoint Inhibitor
Brief: PDS Biotech Announces Exclusive Global License Agreement For Investigational Il-12 Tumor-Targeted Cytokine From Merck KGaA, Darmstadt, Germany
U.S. STOCKS ON THE MOVE-Pixelworks, Gorilla Technology, CSX Corp
U.S. STOCKS ON THE MOVE-Kilroy Realty, Morgan Stanley, T2 Biosystems
PDS Biotech rises as interim cancer trial data shows survival benefits
Brief: Pds Biotechnology Expanded Interim Data In Phase 2 Clinical Trial Investigating Pds0101-Based Triple Combination Therapy
Brief: PDS Biotech Completes First Stage Enrollment In Checkpoint Inhibitor Refractory Arm Of Phase 2 Clinical Trial
PDS Biotechnology jumps on Q3 results, positive cancer drug trial data
Brief: Pds Biotech Reports Q3 Financial Results, Provides Business Update
PDS Biotechnology Corp reports results for the quarter ended in September - Earnings Summary
Brief: Pds Biotech Announces 100% Clinical Response In Cervical Cancer Patients In Mid-stage Study